These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 16763467)

  • 21. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance: what to do if you see an adverse reaction and the consequences.
    Stenver DI
    Eur J Radiol; 2008 May; 66(2):184-6. PubMed ID: 18372136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin safety: an appraisal from the adverse event reporting system.
    Davidson MH; Clark JA; Glass LM; Kanumalla A
    Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy.
    Fujimoto T; Ichikawa H; Akisue T; Fujita I; Kishimoto K; Hara H; Imabori M; Kawamitsu H; Sharma P; Brown SC; Moudgil BM; Fujii M; Yamamoto T; Kurosaka M; Fukumori Y
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S355-8. PubMed ID: 19386506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials.
    Tanimoto A; Kadoya M; Kawamura Y; Kuwatsuru R; Gokan T; Hirohashi S
    J Magn Reson Imaging; 2006 Apr; 23(4):499-508. PubMed ID: 16534755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
    Brown RR; Clarke DW; Daffner RH
    AJR Am J Roentgenol; 2000 Oct; 175(4):1087-90. PubMed ID: 11000170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance contrast agents for neuroimaging. Safety issues.
    Carr JJ
    Neuroimaging Clin N Am; 1994 Feb; 4(1):43-54. PubMed ID: 8130951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.
    Endrikat JS; Dohanish S; Balzer T; Breuer JA
    J Magn Reson Imaging; 2015 Sep; 42(3):634-43. PubMed ID: 25643844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
    Matthews EJ; Frid AA
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements.
    Zhang HL; Ersoy H; Prince MR
    J Magn Reson Imaging; 2006 Mar; 23(3):383-7. PubMed ID: 16463306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visualization of normal and interrupted lymphatic drainage in dog legs with interstitial MR lymphography using an extracellular MR contrast agent, gadopentetate dimeglumine.
    Suga K; Yuan Y; Ogasawara N; Okada M; Matsunaga N
    Invest Radiol; 2003 Jun; 38(6):349-57. PubMed ID: 12908702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging].
    Giersig C
    Radiologe; 2007 Sep; 47(9):794-9. PubMed ID: 17713753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
    Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
    Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intercellular imaging by a polyarginine derived cell penetrating peptide labeled magnetic resonance contrast agent, diethylenetriamine pentaacetic acid gadolinium.
    Guo YM; Liu M; Yang JL; Guo XJ; Wang SC; Duan XY; Wang P
    Chin Med J (Engl); 2007 Jan; 120(1):50-5. PubMed ID: 17254488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors.
    Murphy KP; Szopinski KT; Cohan RH; Mermillod B; Ellis JH
    Acad Radiol; 1999 Nov; 6(11):656-64. PubMed ID: 10894068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study.
    Kittner T; Rudolf J; Fages JF; Legmann P; Aschauer M; Repa I; Alvares MR; Savalegui I; Ittrich H; Geterud K; de Kevviler E; Ayuso J; Lockhart ME; Blum A; Iliasch H; Leisinger G; van Beek EJ; Reid AW; Brown JJ; Yu TC; Flamm SD; Düber C; Judmaier W; Reimer P; Stiskal M; Kramann B; Wolff S; Blankenstein C
    Eur J Radiol; 2007 Dec; 64(3):456-64. PubMed ID: 17412546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
    Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
    J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.